Abstract
The ability to detect single-nucleotide polymorphisms (SNPs) is critical for identifying genetic disorders, assessing pathogen drug resistance, and preventing infection transmission. Achieving a delicate balance across sequence-specific recognition, RNA structural stability, and functional efficacy based on SNP-induced changes in RNA structure is crucial to precise genotyping using RNA-based probes. Here, we report an in silico-designed aptamer-based RNA switch we term FARSIGHT (for Fast Aptamer-based Reporter for SIngle-nucleotide-specific Genotypying through HybridizaTion) that provides rapid, low-leakage, and multiplexed identification of virtually any target sequence in as little as 5 minutes with single-nucleotide specificity. Coupling FARSIGHTs with nucleic acid sequence-based amplification (NASBA) enables robust detection of single-nucleotide mutations at attomolar concentrations with strong fluorescence output. To evaluate these assays, we deploy them to distinguish the SARS-CoV-2 Omicron variant from other SARS-CoV-2 variants (Alpha, Beta, and Gamma) with 100% accuracy on RNA extracted from clinical saliva samples, as confirmed by reverse transcription quantitative polymerase chain reaction and genomic sequencing. FARSIGHTs can thus be easily reprogrammed for genotyping new pathogens with pandemic potential, with potential uses in point-of-care settings for monitoring of emerging infectious diseases and for personalized healthcare applications.
Competing Interest Statement
Z.Y. and A.A.G. have a pending provisional patent application related to this work. A.A.G. is a cofounder of En Carta Diagnostics Inc. The authors declare no other competing interests.
Funding Statement
This work was developed with funding from the Defense Advanced Research Projects Agency (DARPA), Contract No. N66001-23-2-4042; a National Institutes of Health (NIH) Director's New Innovator Award (1DP2GM126892), U01 award (1U01AI148319-01), and R01 award (1R01EB031893); a National Science Foundation (NSF) RAPID award (2029532); Arizona Biomedical Research Centre funds (ADHS16-162400, CTR051763); Canadian Food Inspection Agency funds (39903-200137) and Boston University startup funds to A.A.G. The views, opinions and/or findings expressed are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Arizona State University waived ethical approval for this work. IRB ID: STUDY00011737 Title: Testing for COVID-19 (SARS- Co-2 Virus in Human Samples Determination: NOT HUMAN SUBJECTS RESEARCH DETERMINATION The IRB determined that the proposed activity is not research involving human subjects as defined by DHHS and FDA regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The main data supporting the results in this study are available within the main text and the Supplementary Information. The datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request.
